Filing summary: Flex Pharma, Inc. — Q1 2015
Identity and period: The supplied filing is Flex Pharma, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015; it does not identify Decoy Therapeutics Inc. as the registrant. Flex Pharma is a biotechnology company developing treatments for muscle cramps and spasms, alongside consumer products targeting exercise-associated cramps.
Financial results and position
- Revenue: None to date.
- Operating expenses: $6.02 million, comprising $2.80 million of research and development and $3.22 million of general and administrative expenses.
- Net loss: $6.02 million; basic and diluted loss per share was $0.59.
- Cash flow: $4.14 million used in operating activities and $26,395 used in investing activities. Financing provided $80.84 million, primarily from the IPO. Cash increased by $76.67 million to $110.52 million.
- Liquidity and debt: Current assets were $111.58 million and current liabilities were $1.42 million. Total liabilities were $1.86 million; the company reported no long-term debt.
- Margins: Not meaningful because the company had no revenue. The filing reports operating losses, not positive operating or net margins.
- Accumulated deficit: $14.03 million at March 31, 2015.
Changes and notable items
- In February, the company completed its IPO, selling 5,491,191 shares at $16 per share and receiving approximately $79.9 million in net proceeds. Outstanding preferred stock converted into 6,971,108 common shares.
- Operating expenses rose substantially from the prior comparison period, but that comparison is not like-for-like: the 2014 figures cover only February 26, 2014 (inception) through March 31, 2014, when operations were minimal.
- Stock-based compensation was $1.75 million for the quarter. The company also recorded $400,000 received from early-exercised, unvested options as a liability until the shares vest.
- The company effected a one-for-4.2825 reverse stock split in January 2015.
Outlook, commentary, and risks
- Management expected operating losses and expenses to increase as research, clinical work, public-company costs, and consumer-product launch preparations progressed.
- Management said existing cash was expected to fund the operating plan through at least the next 12 months in the notes, while the MD&A projected funding through mid-2018. Both estimates depend on assumptions and could prove wrong.
- The company anticipated launching its cornerstone consumer product in the first half of 2016 and initiating pre-launch activities in Q2 2015. It reported starting a nocturnal-leg-cramp proof-of-concept study in Q2 2015, after the reporting period.
- Key risks include clinical and regulatory uncertainty, the ability to launch and grow consumer products, the need for future financing, and reliance on key executives and scientific personnel. The filing reported no material legal proceedings and no material changes to previously disclosed risks other than added key-personnel risk.
Important facts for investors to verify
- Confirm the registrant’s identity: the filing is for Flex Pharma, not Decoy Therapeutics.
- Reconcile the differing cash-runway statements: “at least the next 12 months” versus “through mid-2018.”
- Assess whether the planned consumer launch and clinical programs progressed as anticipated; the filing’s Q2 study update is forward-looking relative to this quarter.
- Review the company’s financing needs, spending trajectory, and potential dilution if additional capital is raised.